Pediatrix Medical Group, Inc. (MD) Stock Price & How to Invest

Pediatrix Medical Group (NYSE: MD), founded in 1979 and known as MEDNAX until its 2022 rebrand, provides hospital-based physician staffing and clinical services concentrated in neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and related anesthesiology support. Its clinicians largely staff neonatal intensive care units and other hospital departments under contracts with hospital partners, with revenue driven by patient volumes, payer reimbursement, contract administrative fees and revenue-cycle collections.

The investment picture is one of a mature, low-multiple services business working through a deliberate simplification. Recent results show revenue and margins improving on the strength of pricing (roughly 4% in Q1 2026), better collections, higher administrative fees and increased neonatology acuity, even as patient volumes across service lines drift modestly lower. Management has been divesting non-core practices to sharpen focus on core women's and children's services, improve profitability and pay down debt, which shrinks the revenue base but is intended to lift quality of earnings. The stock trades at a meaningful discount to healthcare-sector peers, reflecting both the restructuring drag and the cost pressures typical of physician-staffing models.

Portfolio restructuring and practice divestitures continue to pressure headline revenue and narrow revenue diversification in a sector with several large, well-capitalized competitors. Physician compensation, salaries and staffing costs can squeeze already tight margins if pricing gains slow. Patient volumes have been declining in parts of the business, including maternal-fetal medicine and neonatology, so growth leans heavily on pricing and payer mix rather than demand. The business is exposed to government and commercial reimbursement policy, hospital-contract renewals and concentration in a small set of subspecialties. Any reversal in payer mix or collections would hit results quickly given the thin operating margins.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Pediatrix Medical Group, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$1.93B
• Q1 2026 net revenue: ~$476M
• Net margin (TTM): ~9%
• P/E ratio: ~12x
• FY2026 adj. EBITDA guidance: ~$280M-$300M
• FY2026 EPS estimate: ~$2.14

Pediatrix trades at a low-teens price-to-earnings multiple, well below the roughly 20x-plus average for healthcare-services peers, which reflects modest growth expectations and restructuring drag. Q1 2026 revenue rose about 4% year on year to roughly $476 million while diluted EPS improved to about $0.36 from $0.24. Full-year adjusted EBITDA is guided near $290 million at the midpoint.

There are three common ways to get MD exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so MD sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where MD fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Pediatrix is a turnaround-flavored, low-multiple physician-services business where pricing and cost discipline are offsetting soft volumes and a smaller footprint after divestitures.

Whether MD is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MD a buy?, and where the stock could go from here in the MD stock forecast.

For income investors, whether MD pays a dividend and how the payout looks is covered in does MD pay a dividend?